Search

Author/Creator Choi, Michael Y.

2. Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576. (22nd January 2022)

Authors:
Castro, Januario E.; Lengerke-Diaz, Paula A.; Velez Lujan, Juliana; Choi, Michael Y.; Moreno-Cortes, Eider F.; Forero, Jose V.; Garcia-Robledo, Juan Esteban; Jacobs, Chaja; McCarthy, Colin; Heinen, Alaina; Amaya-Chanaga, Carlos I.; Kipps, Thomas J.
Other Names:
Matutes Estella M. Academic Editor.
Journal:
Advances in hematology
Issue:
Volume 2022(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. S793 Full Target Engagement With Saturation of α4β7 Integrin Receptor Occupancy Resulting in Changes in Subset of Lymphocytes by MORF-057 Following 200 Mg Daily Dosing in Healthy Subjects. (October 2022)

Authors:
Choi, Michael Y.; Jones, John P.; Lee, Dooyoung; Mangada, Maloy M.; Hussain, Ali; Thosar, Shilpa; Cui, Dan; Wu, Yujun; Chae, Mimi S.; Soo, Carolyn L.; Nguyen, Hanh; JeBailey, Lellean; Ray, Adrian S.; Rogers, Bruce N.; Bain, Gerard
Other Names:
Chavan Ajit presenter.
Journal:
American journal of gastroenterology
Issue:
Volume 117:Number 10(2022)supplement 10S
Page Start:
e565
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗